Market data
Select a section
Novacyt S.A. (CDI)
(NCYT)
Sector: Medical Equipment and Services
47.00p
0.20p 0.43
Last updated: 10:17:38
1 day chart
6 month chart
Today's buy and sell prices
| The price at which you can buy a share or investment. It is usually higher than the bid (sell) price. It’s the price you are being offered. Offer | 47.40p |
|---|---|
| The price at which you can sell a share or investment. It is lower than the offer (buy) price. Bid | 46.10p |
| The difference between the bid and offer prices expressed as a percentage. When you buy shares you pay a higher price than you get when you sell them. The difference between these prices is the profit made by the market maker who puts the deals together. Spread | 2.74 |
Today's trading
| Range The lowest and the highest price a share has reached in the trading day. | 46.14p-47.40p |
|---|---|
| The lowest and the highest price a share has reached in the trading day. Volume | 43,930.00 |
| The lowest and the highest price a share has reached in the trading day. Today's open | 47.00p |
| At the end of the trading day there is an official closing price for every share. The previous session’s close is used as the base to calculate the following day’s price changes. Previous close | 48.50p |
Yearly summary
| The highest and lowest prices the shares have traded at over a rolling 52-week period. It gives you a good indication of how the share price is performing now relative to its recent past performance. 52wk range | 43.73p-118.00p |
|---|
Fundamentals and health
| A measure of the company's worth on the stock market. We display the previous closing share price multiplied by the number of shares in issue. Market capitalisation | £33.19 |
|---|---|
| The number of shares a company has in circulation, in millions. Shares in issue | 70.63 |
| The main valuation used by investors and a way of gauging whether a company's share price is cheap or expensive compared to competitors. You get PE by dividing the share price by the earnings per share (EPS). Our figure is last basic unadjusted - reported - annual EPS / current share price x 100. Companies also quote adjusted EPS figures to remove the effect of one-off exceptional figures from the profit figures. There is debate among investors as to whether this should be used. We use basic EPS – the purest figure. PE ratio | n/a |
| PEG ratio | n/a |
| An important ratio for showing how much profit after tax and other deductions (net profit) is actually being earned per share. You divide the net profit by the number of shares in issue. Expressed in pence per share. Looking at whether the EPS is rising or falling over time is one of the most important indicators of whether a company is really making money for its shareholders. Our figure is undiluted, meaning it is not adjusted for exceptional costs. EPS | -31.00p |
| Earnings per share growth illustrates the growth of earning per share over the last two reporting periods. It helps investors identify stocks that are increasing or decreasing in profitability. A minus sign indicates negative growth. EPS growth | n/a |
| Return on capital employed measures a company's profitability in relation to how much capital is invested in the business. Generally, the higher the figure the better but with all these ratios it is best to compare companies from the same sector. A high double digit figure may mean a company has an advantage over its competitors because of a unique product but an oil company, for example, will have higher capital outlay than an online retailer. Our formula: [Pre-tax profit / (total assets – short-term liabilities)] * 100 ROCE | -21.77 |
| Also known as the acid test ratio, it's a quick guide to how well a company can pay its short-term debts. Above 1 is considered healthy. A ratio of 1.5 would mean the company has £1.50 of liquid (accessible) assets to cover each £1 of debt (current liabilities). Formula: Current assets minus inventory / current liabilities. Quick ratio | 5.12 |
| Indicates whether a company can convert assets into cash to pay its debts within the next 12 months. It is calculated as current assets / current liabilities for the same period but will display as '0' for companies such as banks that don't distinguish between short and long-term liabilities. Current ratio | 5.25 |
| The amount of money a company paid to a shareholder for each share they own over the past 12 months, expressed in pence. Total dividends per share | n/a |
| The dividends paid per share over the past 12 months (interim plus final) as a percentage of the share price. Our figure includes recurring special dividends. Dividend yield | n/a |
| The number of times the dividend could have been paid out from net profits. It is a good indicator of the company's ability to pay the dividend and its level of generosity. Formula: earnings per share / dividends per share. More than 2 is considered healthy, less than 1.5 may hint that a dividend is at risk of being cut. Dividend cover | n/a |
| Dividend per share growth | n/a |
Novacyt S.A. (CDI) Fundamentals
The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.
Novacyt S.A. (CDI) Regulatory news
| Date | Time | Headline | Source |
|---|---|---|---|
| 14/11/2024 | 13:20 | Further expansion of cost reduction programme | RNS |
| 01/11/2024 | 12:45 | Liquidity Agreement and Total Voting Rights | RNS |
| 31/10/2024 | 07:00 | Directorate Change | RNS |
| 17/10/2024 | 07:00 | IVDR accreditation | RNS |
| 08/10/2024 | 12:30 | Closure of IT-IS International | RNS |
| 01/10/2024 | 12:30 | Liquidity Agreement and Total Voting Rights | RNS |
| 26/09/2024 | 07:01 | Interim Results | RNS |
| 26/09/2024 | 07:00 | Directorate Change | RNS |
| 20/09/2024 | 17:30 | Rule 19.6(c) confirmation of post-offer intentions | RNS |
| 12/09/2024 | 07:00 | Notice of Results | RNS |
Novacyt S.A. (CDI) Latest trades
Latest trades
| Date | Time | Price | Amount | Value | Type | Buy / sell |
|---|---|---|---|---|---|---|
| 25/11/2024 | 10:10:02 | 46p | 3,500 | £1,610.00 | O | Sell |
| 25/11/2024 | 10:10:00 | 47p | 2,514 | £1,181.58 | O | Buy |
| 25/11/2024 | 10:10:00 | 47p | 120 | £56.40 | O | Buy |
| 25/11/2024 | 10:09:02 | 47p | 4,251 | £1,997.97 | O | Buy |
| 25/11/2024 | 10:09:02 | 47p | 4,251 | £1,997.97 | O | Buy |
Analysis
| Buy | Sell | |
|---|---|---|
| Quantity | 6 | 10 |
| Volume | 16,021 | 27,909 |
| Value | £7,588 | £13,090 |
Novacyt S.A. (CDI) Director dealings
| Trade date | Director | Volume / Price | Trade value | Trade type |
|---|---|---|---|---|
| 11/07/2022 | Edwin Snape | 17,919 @ 0.00 | 0.00 | Transfer To |
| 11/07/2022 | Edwin Snape | 17,919 @ 0.00 | 0.00 | Transfer From |
| 07/07/2022 | James Wakefield | 7,000 @ 117.00p | £8,190.00 | Buy |
| 25/03/2022 | David Allmond | 43,500 @ 231.00p | £100,485.00 | Buy |
| 25/03/2022 | David Allmond | 43,500 @ 231.00p | £100,485.00 | Buy |
| 15/03/2022 | Jean-Pierre Crinelli | 5,800 @ €2.58 | €14,964.00 | Buy |
| 18/03/2022 | Jean-Pierre Crinelli | 3,208 @ 241.00p | £7,731.28 | Buy |
| 14/03/2022 | James McCarthy | 2,360 @ 212.00p | £5,003.20 | Buy |
| 14/03/2022 | James McCarthy | 37,310 @ 201.00p | £74,993.10 | Buy |
Novacyt S.A. (CDI) Broker views
| Date | Broker | Recomm. | Old target price | New target price | Notes |
|---|---|---|---|---|---|
| 18/08/2021 | Numis | buy | - | 570.00p | reiteration |
| 29/06/2021 | Numis | buy | - | 570.00p | reiteration |
| 17/05/2021 | Numis | buy | - | 570.00p | reiteration |
Novacyt S.A. (CDI) News
| Date | Time | Headline |
|---|---|---|
| 20/08/2024 | 07:43 | Why investing in vaccine companies can be hazardous for your financial health - even if fears of a monkeypox pandemic have sparked a flurry of speculation, writes RUTH SUNDERLAND |
| 03/07/2023 | 07:38 | BUSINESS LIVE: London IPOs plunge; Gerry Murphy named Tesco chair |
| 09/12/2022 | 14:55 | SMALL CAP MOVERS: Bonhill shares skyrocket on takeover bid |
| 09/07/2022 | 19:36 | STOCKS TO WATCH: Burberry | Love Hemp | Greggs |
| 23/04/2021 | 17:48 | MARKET REPORT: Pandemic star Novacyt back in demand |
| 09/04/2021 | 18:11 | MARKET REPORT: Novacyt crashes down to earth |
| 27/04/2020 | 18:00 | MARKET REPORT: British pharma shines with coronavirus test |
| 17/04/2020 | 17:49 | Novacyt shoots to stock market stardom after developing diagnostic test for Covid-19 |
| 08/04/2020 | 17:54 | MARKET REPORT: Coronavirus testing race lifts shares in pharmaceutical firms |
